Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 92, Issue , 2015, Pages 63-65

  Lagarde, M ^a   Hachem, M ^a   Bernoud Hubac, N ^a   Picq, M ^a   Vericel E ^a   Guichardant, M ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

Blood brain barrier; Metabolism; Stroke

Indexed keywords

1 ACETYL, 2 DOCOSAHEXAENOYL GLYCEROPHOSPHOCHOLINE; 1 LYSO,2 DOCOSAHEXAENOYL GLYCEROPHOSPHOCHOLINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ALBUMIN; CARBON 14; DOCOSAHEXAENOIC ACID; GLYCEROPHOSPHORYLCHOLINE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; 1-ACETYL-2-DOCOSAHEXAENOYL-GLYCEROPHOSPHOCHOLINE; NEUROPROTECTIVE AGENT; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID;

ACETYLATION; ARTICLE; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; BRAIN LEVEL; CHEMICAL STRUCTURE; ERYTHROCYTE; ESTERIFICATION; ISOTOPE LABELING; LIPID METABOLISM; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK; ANIMAL; BRAIN; DRUG EFFECTS; HUMAN; METABOLISM; PATHOLOGY; STROKE;

RATTUS;

ANIMALS; BRAIN; HUMANS; NEUROPROTECTIVE AGENTS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; STROKE;

EID: 84921439093     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.01.005     Document Type: Article

References (19)

1. Crawford M.A., Bloom M., Broadhurst C.L., Schmidt W.F., Cunnane S.C., Galli C., Gehbremeskel K., Linseisen F., Lloyd-Smith J., Parkington J. Evidence for the unique function of docosahexaenoic acid during the evolution of the modern hominid brain. Lipids 1999, 34(Suppl.):S39-S47. (Review).
2. Gordon N. Nutrition and cognitive function. Brain Dev. 1997, 19:165-170.
3. Harris WS. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol. Res. 2007, 55:217-223.
4. Thiès F., Delachambre M.C., Bentejac M., Lagarde M., Lecerf J. Unsaturated fatty acids esterified in 2-acyl-l-lysophosphatidylcholine bound to albumin are more efficiently taken up by the young rat brain than the unesterified form. J. Neurochem. 1992, 59:1110-1116.
5. Thies F., Pillon C., Moliere P., Lagarde M., Lecerf J. Preferential incorporation of sn-2 lysoPC DHA over unesterified DHA in the young rat brain. Am. J. Physiol. 1994, 267:R1273-R1279.
6. Bernoud N., Fenart L., Molière P., Dehouck M.P., Lagarde M., Cecchelli R., Lecerf J. Preferential transfer of 2-docosahexaenoyl-1-lysophosphatidylcholine through an in vitro blood-brain barrier over unesterified docosahexaenoic acid. J. Neurochem. 1999, 72:338-345.
7. Plückthun A., Dennis E.A. Acyl and phosphoryl migration in lysophospholipids: importance in phospholipid synthesis and phospholipase specificity. Biochemistry 1982, 21:1743-1750.
8. Croset M., Brossard N., Polette A., Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem. J. 2000, 345:61-67.
9. Polette A., Deshayes C., Chantegrel B., Croset M., Armstrongb J.M., Lagarde M. Synthesis of acetyl,docosahexaenoyl-glycerophosphocholine and its characterization using nuclear magnetic resonance. Lipids 1999, 34:1333-1337.
10. M. Lagarde, M. Guichardant, M. Picq, S. Michaud, A. Doutheau, Method for preparing acetyl,docosahexaenoylglycerophosphocholine and use thereof for the delivery of polyunsaturated fatty acids, WO/2008/068413.
11. Picq M., Chen P., Perez M., Michaud M., Véricel E., Guichardant M., Lagarde M. DHA metabolism: targeting the brain and lipoxygenation. Mol. Neurobiol. 2010, 42:48-51.
12. Brossard N., Croset M., Normand S., Pousin J., Lecerf J., Laville M., Tayot J.L., Lagarde M. Human plasma albumin transports [13C]docosahexaenoic acid in two lipid forms to blood cells. J. Lipid Res. 1997, 38:1571-1582.
13. Lemaitre-Delaunay D., Pachiaudi C., Laville M., Pousin J., Armstrong M., Lagarde M. J. Lipid Res. 1999, 40:1867-1874.
14. Belayev L., Khoutorova L., Atkins K.D., Bazan N.G. Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke 2009, 40:3121-3126.
15. Chauveau F., Cho T.H., Perez M., Guichardant M., Riou1 A., Aguetta P., Picq M., Lagarde M., Berthezène Y., Nighoghossian N., Wiart M. Brain-targeting form of docosahexaenoic acid for experimental stroke treatment: MRI evaluation and anti-oxidant impact. Curr. Neurovasc. Res. 2011, 8:95-102.
16. Vargaftig B.B., Chignard M., Benveniste J., Lefort J., Wal F. Background and present status of research on platelet-activating factor (PAF-acether). Ann. N. Y. Acad. Sci. 1981, 370:119-137.
17. Larsen G.L., Henson PM. Mediators of inflammation. Annu. Rev. Immunol. 1983, 1:335-359.
18. McManus LM., Deavers S.I. Platelet activating factor in pulmonary pathobiology. Clin. Chest Med. 1989, 10:107-118.
19. M. Lagarde, E. Véricel, M. Picq, N. Bernoud-Hubac, M. Guichardant, Phosphatidylcholines en tant que modulateurs de l[U+05F3]activité du facteur d[U+05F3]activation plaquettaire, Patent 2011/58149.